Michael Foote, MD

Articles

A panel of 5 experts on colorectal cancer

Future Perspectives on MRD Testing in Colorectal Cancer

John Strickler, MD;Aparna Raj Parikh, MD, MS ;Stacey A. Cohen, MD;Arvind Dasari, MD, MS;Michael Foote, MD

April 4th 2024

The expert panel concludes its discussion with a focus on the future of MRD testing in colorectal cancer, highlighting the treatment landscape’s current strengths and challenges.

BESPOKE CRC: The Impact of ctDNA-Guided Therapy in CRC

John Strickler, MD;Aparna Raj Parikh, MD, MS ;Stacey A. Cohen, MD;Arvind Dasari, MD, MS;Michael Foote, MD

March 28th 2024

Focusing on the BESPOKE CRC study, John H. Strickler, MD, reviews recent updates presented at ASGO GI 2024 and discusses subset analyses from the trial.

The Study Design and Early Findings from the INTERCEPT Study in CRC

John Strickler, MD;Aparna Raj Parikh, MD, MS ;Stacey A. Cohen, MD;Arvind Dasari, MD, MS;Michael Foote, MD

March 28th 2024

An overview of the rationale and study design of the INTERCEPT study in patients with colorectal cancer, with a focus on the early key findings.

Arvind N. Dasari, MD, MS, an expert on colorectal cancer

Patient Profile 3: A 62-Year-Old Woman with Colon Cancer

John Strickler, MD;Aparna Raj Parikh, MD, MS ;Stacey A. Cohen, MD;Arvind Dasari, MD, MS;Michael Foote, MD

March 21st 2024

Arvind N. Dasari, MD, MS, presents the third patient profile of the discussion, a 62-year-old woman with colon cancer, highlighting the role of MRD testing in guiding treatment decisions in the surveillance setting.

Stacey Cohen, MD, an expert on colorectal cancer

Initial Results from Phase 2 COBRA Study in Colorectal Cancer

John Strickler, MD;Aparna Raj Parikh, MD, MS ;Stacey A. Cohen, MD;Arvind Dasari, MD, MS;Michael Foote, MD

March 21st 2024

Stacey Cohen, MD, reviews the initial results from the phase 2 COBRA study focused on ctDNA as a predictive biomarker in adjuvant chemotherapy for patients with stage II colon cancer.

Rationale and Study Design of CIRCULATE-NORTH AMERICA in CRC

John Strickler, MD;Aparna Raj Parikh, MD, MS ;Stacey A. Cohen, MD;Arvind Dasari, MD, MS;Michael Foote, MD

March 14th 2024

Arvind N. Dasari, MD, MS, gives an overview of the rationale and study design of the phase 2/3 CIRCULATE-NORTH AMERICA clinical trial.

Colorectal Cancer: Key Updates from GALAXY At ASCO GI 2024

John Strickler, MD;Aparna Raj Parikh, MD, MS ;Stacey A. Cohen, MD;Arvind Dasari, MD, MS;Michael Foote, MD

March 14th 2024

Experts on colorectal cancer provide comprehensive insights on the GALAXY study, highlighting key updates that were presented at ASCO GI 2024.

Aparna Parikh, MD, an expert on colorectal cancer

DYNAMIC Trial: ctDNA Analysis Guiding Adjuvant Therapy in Early-Stage CRC

John Strickler, MD;Aparna Raj Parikh, MD, MS ;Stacey A. Cohen, MD;Arvind Dasari, MD, MS;Michael Foote, MD

March 7th 2024

Aparna Parikh, MD, reviews the DYNAMIC trial, which is focused on ctDNA-guided adjuvant therapy in early-stage colorectal cancer.

Patient Profile 2: A 39-Year-Old Woman with High-Risk Stage II CRC

John Strickler, MD;Aparna Raj Parikh, MD, MS ;Stacey A. Cohen, MD;Arvind Dasari, MD, MS;Michael Foote, MD

March 7th 2024

Stacey Cohen, MD, presents the case of a 39-year-old woman with high-risk stage II colorectal cancer, highlighting how ctDNA helped inform treatment selection.

COSMOS-CRC-03: ctDNA and Recurrence in Colorectal Cancer

John Strickler, MD;Aparna Raj Parikh, MD, MS ;Stacey A. Cohen, MD;Arvind Dasari, MD, MS;Michael Foote, MD

February 29th 2024

The expert panel provides a comprehensive overview of the COSMOS-CRC-03 study and touch on the importance of also looking at real-world data.

Prospective Trial Data on MRD Testing in Early-Stage CRC

John Strickler, MD;Aparna Raj Parikh, MD, MS ;Stacey A. Cohen, MD;Arvind Dasari, MD, MS;Michael Foote, MD

February 29th 2024

An overview of prospective trial data surrounding MRD testing in early-stage CRC and the impact of these findings on the overall treatment landscape.

Michael Foote, MD, an expert on colorectal cancer

Patient Profile 1: A 50-Year-Old With Stage III Colorectal Cancer

John Strickler, MD;Aparna Raj Parikh, MD, MS ;Stacey A. Cohen, MD;Arvind Dasari, MD, MS;Michael Foote, MD

February 22nd 2024

Michael Foote, MD, presents the case of a 50-year-old man with stage III colorectal cancer, highlighting the role of MRD testing in patient monitoring and treatment management.

MRD Testing Practices in Colorectal Cancer

John Strickler, MD;Aparna Raj Parikh, MD, MS ;Stacey A. Cohen, MD;Arvind Dasari, MD, MS;Michael Foote, MD

February 22nd 2024

GI medical oncologists discuss MRD testing practices in colorectal cancer and provide insights on challenges associated with testing.

Platforms for Testing MRD in CRC

John Strickler, MD;Aparna Raj Parikh, MD, MS ;Stacey A. Cohen, MD;Arvind Dasari, MD, MS;Michael Foote, MD

February 15th 2024

Arvind N. Dasari, MD, MS, provides clinical insights on MRD testing modalities, highlighting factors that inform the decision on which platform to use in practice.

Testing for MRD With ctDNA in Colorectal Cancer (CRC)

John Strickler, MD;Aparna Raj Parikh, MD, MS ;Stacey A. Cohen, MD;Arvind Dasari, MD, MS;Michael Foote, MD

February 15th 2024

A panel of medical oncologists introduce themselves and provide an overview of circulating tumor DNA (ctDNA) and how it relates to MRD (minimal residual disease) testing in colorectal cancer (CRC).

Unmet Needs and Future Perspectives on Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

June 5th 2023

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in colorectal cancer.

Trials Focused on ctDNA in Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 29th 2023

An expert panel discusses clinical trials focused on circulating tumor DNA in guiding treatment selection in colorectal cancer.

Arvind Dasari, MD, MS, an expert on colorectal cancer

SUNLIGHT and FRESCO-2 Trials in Refractory Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 29th 2023

An overview of the SUNLIGHT and FRESCO-2 studies in the refractory colorectal cancer space.

Colorectal Cancer: Insights on ctDNA and Retesting for HER2 Expression

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 22nd 2023

A panel of experts discuss the role of ctDNA and their practices for retesting HER2 expression to guide treatment for colorectal cancer.

T-DXd in Patients With HER2+ Metastatic Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 22nd 2023

A comprehensive overview of trastuzumab deruxtecan (T-DXd) as a treatment for patients with HER2+ metastatic colorectal cancer.

Patient Profile: A 40-Year-Old Woman With Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 15th 2023

Experts on colorectal cancer present the case of a 40-year-old woman with CRC, who receives later-line treatment with trastuzumab deruxtecan, and share their initial thoughts.

Metastatic CRC: Role of ctDNA in Treatment Selection

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 15th 2023

Insights on the role of circulating tumor DNA in treatment selection for patients with metastatic colorectal cancer.

PARADIGM Trial: Recent Data on EGFR-Targeting Therapy for mCRC

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 8th 2023

Arvind Dasari, MD, MS, reviews the PARADIGM study on EGFR-targeting therapy in metastatic colorectal cancer.

Patient Profile: A 47-Year-Old Woman With HER2+ CRC and Early Disease Progression

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 8th 2023

Expert oncologists present the case of a 47-year-old woman with colorectal cancer and early disease progression, and discuss treatment options with the ongoing MOUNTAINEER-03 study.

MOUNTAINEER: Tucatinib Plus Trastuzumab in HER2+ Metastatic Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 1st 2023

Experts on HER2+ metastatic colorectal cancer review the MOUNTAINEER study on tucatinib plus trastuzumab.

Treatment Landscape for HER2+ Metastatic Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 1st 2023

An overview of the treatment landscape for HER2+ metastatic colorectal cancer and recent updates to the NCCN Guidelines.

Overview of HER2+ Metastatic Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

April 24th 2023

Expert oncologists discuss the landscape surrounding HER2+ metastatic CRC, including recommendations for biomarker testing and an overview of scoring criteria.

Patient Profile: A 46-Year-Old Woman With HER2+ Metastatic Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

April 24th 2023

A panel of expert oncologists present the case of a 46-year-old woman with HER2+ metastatic colorectal cancer, who is treated with tucatinib in the second-line setting.